Trader should watch for the full PYNNACLE data update at a medical conference in Q4 2026, the NDA submission in Q1 2027, and any FDA feedback on the accelerated approval pathway.
Price Chart
Executive Summary
PMV Pharma announced updated interim Phase 2 data for rezatapopt in TP53 Y220C-mutant platinum-resistant/refractory ovarian cancer, showing a 46% ORR in 76 evaluable patients with a median duration of response of 10.0 months. The company also disclosed FDA feedback supporting its plan to submit an NDA for accelerated approval in Q1 2027, with a full PYNNACLE data update expected at a medical conference in Q4 2026.
Key Facts
- 46% ORR (35/76 evaluable patients) with 4 confirmed complete responses and 29 confirmed partial responses in ovarian cancer cohort.
- Median duration of response of 10.0 months among confirmed responders; median time to response 1.3 months.
- FDA interaction supports NDA submission strategy for accelerated approval; NDA submission planned for Q1 2027.
- Rezatapopt granted Fast Track designation and Orphan Drug Designation for TP53 Y220C-positive ovarian/fallopian tube/primary peritoneal cancer.
- Safety profile favorable with low 5% discontinuation rate due to treatment-related AEs; mostly Grade 1-2 events.
- Full PYNNACLE Phase 2 pivotal trial data update (primary analysis from ovarian cohort and all cohorts) expected Q4 2026.
Financial Impact
Not stated in filing: no revenue, no cash runway figures, and no market cap comparison provided in the press release.
Risk Factors
- FDA may require additional data or a confirmatory Phase 3 trial before granting accelerated approval, even with positive FDA meeting feedback.
- Single-arm Phase 2 data may not translate to a statistically robust benefit versus standard-of-care; durability endpoints could be weaker at primary analysis.
- PMV Pharma is a clinical-stage company with no approved products and limited cash runway — financing risk if NDA timelines slip.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3353671 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $1.78 | awaiting T+20 | — | $1.22 (−31.46%) |
Aug 31, 2026 7w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.22 (+5.43%) |
Aug 31, 2026 7w ago | 8-K | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.22 (−5.43%) |
Aug 31, 2026 7w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.22 (+5.43%) |
Aug 31, 2026 7w ago | Press Release | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.22 (−5.43%) |
Aug 14, 2026 10w ago | 8-K | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.22 (−3.17%) |
Aug 14, 2026 10w ago | Press Release | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.22 (−3.17%) |
May 12, 2026 23w ago | 8-K | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.22 (−14.08%) |
May 12, 2026 23w ago | Press Release | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.22 (−14.08%) |
Apr 22, 2026 26w ago | DEFA14A | $1.48 $1.31 | ▼ −11.49% | ▼ −14.65% | $1.22 (−17.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers